Skip to main content
Signal8

BriaCell Therapeutics Corp. (BCTXL)

Sector: Pharmaceutical Preparations

Industry: Biotechnology

BriaCell Therapeutics Corp. logo

BriaCell Therapeutics Corp.

NASDAQ:BCTXLSub-class of BCTXHealthcare
-2.44%$0.8000
CLOSED
Mkt Cap$6.99M
EV-
Float8.72M
O/S8.73M
VOL79K sh
$ Vol$63K
RVOL4.64×
Inst Own-
SI0.1%
Net Cash/Sh-
Dilution
BriaCell Therapeutics Corp. logoNASDAQ:BCTXLClosed$0.8000-2.44%
Historical Data
DateOpenHighLowCloseVolume
Nov 17, 20260.81000.91000.79000.800078,676
Nov 16, 20260.89000.96170.77500.820010,498
Nov 13, 20260.97000.98000.87070.870817,530
Nov 12, 20260.89000.95000.89000.920010,901
Nov 11, 20260.97000.97000.92000.97009,024
Nov 10, 20261.011.020.85000.980022,071
Nov 9, 20261.021.050.99000.997513,784
Nov 6, 20260.89991.000.87500.975040,531
Nov 5, 20260.83000.90000.78500.810039,246
Nov 4, 20260.83660.83660.81300.825013,630
Nov 3, 20260.82000.84000.80500.83995,651
Nov 2, 20260.70000.86170.70000.75008,800
Oct 30, 20260.83000.90000.72000.810522,409
Oct 29, 20260.87500.90000.83000.90003,403
Oct 28, 20260.88000.89270.84000.84005,482
Oct 27, 20260.79000.87000.79000.85003,660
Oct 26, 20260.88000.88000.70020.87005,663
Oct 23, 20260.89900.90000.88500.889911,577
Oct 22, 20260.90990.91000.88500.90258,947
Oct 21, 20260.92000.93990.90000.930017,170
Analyst Coverage
No analyst coverage for this companyNo ratings, price targets, or covering firms on file.
Insider Trades
No insider transactions for this companyForeign private issuers and non-reporting entities don't file Form 4/5.
Shareholders
--
Institutional
(11)
--
Insiderⓘ
(0)
--
5%+ Owners
(0)
--
Unattributed (incl. retail)ⓘ
Sources: 13F
Insiders & Institutional Holders
About

BriaCell Therapeutics Corp. is an immuno-oncology biotechnology company primarily focused on developing innovative immunotherapies to combat cancer.

The firm's leading experimental drug, Bria-IMT, is currently undergoing Phase I/IIa clinical investigation. This crucial study evaluates its effectiveness when utilized in conjunction with immune checkpoint inhibitors for treating breast cancer. Beyond its flagship program, BriaCell has forged a collaborative research and development partnership with the National Cancer Institute (NCI). This alliance is dedicated to progressing Bria-OTS, a personalized immunotherapy designed for advanced breast cancer patients, and BriaDx, a proprietary diagnostic assay.

The company's main offices are situated in West Vancouver, Canada.

Key Metrics
Market Cap$6.99M
Enterprise Value--
P/E Ratio--
Est. Net Cash/Share--
Institutional Ownership--

based on 8.73M shares outstanding

SectorHealthcare
IndustryBiotechnology
ExchangeNASDAQ
CountryCACA
IPO DateJan 14, 2026
Shares Outstanding8.73M
Authorized Shares
Float8.72M
52-Week Range
$0.7900$1.23
$0.8000(2nd percentile)
Volume
Average Daily Volume16.95K
78.68K today vs 16.95K avg(+364%)

30d Avg

16.95K

60d Avg

17.30K

90d Avg

16.66K

Earnings
Dividend History
No dividend history available
Compliance Status
Loading compliance data...

BriaCell Therapeutics Corp. (NASDAQ: BCTXL) traded at $0.8000 on Nov 17, 2026, down 2.44% from the previous close of $0.8200. 52-week range: $0.7900 to $1.23. The company is in the Healthcare sector (Biotechnology).